JoyceMichelleCortesMD

PubMed

• Research needs in breast cancer.
  Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA> ;Ann. Oncol.. 2016-11-09
• Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic...
  Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, ...> ;Ann. Oncol.. 2016-11-01
• New drugs in acute myeloid leukemia.
  Kadia TM, Ravandi F, Cortes J, Kantarjian H> ;Ann. Oncol.. 2016-05-01
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
  Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gr...> ;Ann. Oncol.. 2016-03-01
• Differences in attitudes and beliefs toward end-of-life care between hematologic and solid tumor oncology specialists.
  Hui D, Bansal S, Park M, Reddy A, Cortes J, Fossella F, Bruera E> ;Ann. Oncol.. 2015-07-01
• Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
  De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard F, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Taberne...> ;Ann. Oncol.. 2014-09-01
• Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results fro...
  Swain SM, Baselga J, Miles D, Im Y, Quah C, Lee LF, Cortés J> ;Ann. Oncol.. 2014-06-01
• Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
  Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M> ;Ann. Oncol.. 2014-03-01
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
  Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J> ;Ann. Oncol.. 2014-03-01
• Survival of women with inflammatory breast cancer: A large population based study.
  Dawood, S.,Lei, X.,Dent, R.,Gupta, S.,Sirohi, B.,Cortes, J.,Cristofanilli, M.,Buchholz, T.,Gonzalez-Angulo, A. M.> ;Ann. Oncol.. 2014 Mar 29
• First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
  Miles DW, Diéras V, Cortés J, Duenne A, Yi J, O'Shaughnessy J> ;Ann. Oncol.. 2013-11-01
• Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
  Cortés J, Baselga J, Im Y, Im S, Pivot X, Ross G, Clark E, Knott A, Swain SM> ;Ann. Oncol.. 2013-10-01
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positi...
  Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai Y, Ratnayake J, McNally V, Ross G, Cortés J> ;Ann. Oncol.. 2013-09-01
• Management of the axilla in early breast cancer patients in the genomic era.
  Oliveira M, Cortés J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz E, Ortega V, Pérez J, Saura C, Vidal M, Rubio IT, Di Cosimo S> ;Ann. Oncol.. 2013-05-01
• Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
  Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS> ;Ann. Oncol.. 2012-12-01
• mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.
  Villarreal-Garza C, Cortes J, Andre F, Verma S> ;Ann. Oncol.. 2012-10-01
• Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
  Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silv...> ;Ann. Oncol.. 2012-05-01
• Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.
  Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S> ;Ann. Oncol.. 2012-04-01
• Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tu...
  Soria J, Cortes J, Massard C, Armand J, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier J, Beliveau M, Martell RE, Baselga J> ;Ann. Oncol.. 2012-02-01
• Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
  Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, Bas...> ;Ann. Oncol.. 2010-07-01
• BRCA2 germ-line mutations in Spanish male breast cancer patients.
  Díez O, Cortés J, Domènech M, Pericay C, Brunet J, Alonso C, Baiget M> ;Ann. Oncol.. 2000-01-01
• Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
  Vey N, Kantarjian H, Tran H, Beran M, O'Brien S, Bivins C, Giles F, Cortes J, Cheson B, Arbuck S, Estey E> ;Ann. Oncol.. 1999-05-01
• Join now to see all